
FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment
Recently, the U.S. Food and Drug Administration (FDA) approved LEQEMBI IQLIK® (lecanemab-irmb) subcutaneous injection as a starting treatment option for certain patients with early Alzheimer’s disease.










